People · Operator
Named in public records as an officer, director or promoter · active 2013–2022 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Exagen Diagnostics Inc | — | Biotechnology | Series B | $88.5M | $261.4M | 2013 |
| Ophirex, Inc. | — | Other | Series B | $21.5M | $179.8M | 2022 |
Curt R. LaBelle at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Curt R. LaBelle on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Blivin | 1 | 14 |
| Dinesh Patel | 1 | 13 |
| Scott L. Glenn | 1 | 9 |
| Brian Birk | 1 | 8 |
| James L.L. Tullis | 1 | 6 |
| Scott Glenn | 1 | 4 |
| Waneta C. Tuttle | 1 | 4 |
| Daniel C. Burrell | 1 | 3 |
| Lisa Davis | 1 | 3 |
| Michael J. Walsh | 1 | 2 |
| Todd Stevens | 1 | 2 |
| John Bessone | 1 | 2 |
| Ron Rocca | 1 | 2 |
| Michael R. Walsh | 1 | 2 |
| Howard J. Pien | 1 | 2 |
| Thierry R. Dervieux | 1 | 1 |
| David J. Bilvin | 1 | 1 |
| Wendy J. Swedick | 1 | 1 |
| Thierry J. Dervieux | 1 | 1 |
| Wendy L. Swedick | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.